Search company, investor...


Founded Year



Unattributed - II | Alive

Total Raised


Last Raised

$1.2M | 8 yrs ago

About Neuronascent

Neuronascent is focused on the discovery and development of therapies for Alzheimer's disease, depression, and stroke based on the science of neurogenesis that: (1) Reduce the loss of neurons (2) Restore and replace damaged neurons (3) Promote the formation of new neurons (4) Reverse cognitive loss

Headquarters Location

6030 Day Break Circle A150 - PMB244

Clarksville, Maryland, 21029,

United States


Missing: Neuronascent's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neuronascent's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Neuronascent

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neuronascent is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Neuronascent Patents

Neuronascent has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Neurotrauma, Transcription factors, Developmental neuroscience, Alzheimer's disease, Neurological disorders


Application Date


Grant Date



Related Topics

Neurotrauma, Transcription factors, Developmental neuroscience, Alzheimer's disease, Neurological disorders



Latest Neuronascent News

Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

Nov 8, 2022

Clarksville, Maryland, UNITED STATES ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures” has been accepted for a poster presentation at 15th Clinical Trials on Alzheimer’s Disease (CTAD 2022) to be held in San Francisco, Calif., on Nov. 29 through Dec. 2, 2022. The primary goal of this trial was to assess the safety and tolerability of oral NNI-362 in healthy aged subjects. “These findings are very encouraging since the pre-clinical results are indeed being mimicked in the clinic, including both safety and potential efficacy markers, as we move toward a Phase 2 proof-of-concept trial,” said founder and CEO Judith Kelleher-Andersson, PhD. Dr. R. Scott Turner, MD, PhD, director of the Memory Disorders Program, Georgetown University, will be presenting this data at CTAD 2022 as one of the accepted late-breaking posters. The Phase 1a single ascending and multiple ascending dose (SAD + MAD) trial of NNI-362 demonstrated a significant reduction from pretreatment-baseline of an Alzheimer’s disease progression biomarker, with no change observed with placebo in healthy aged subjects. This placebo-controlled, randomized trial was fully supported by a grant from the National Institute on Aging (NIA, part of the National Institutes of Health). In topline results, NNI-362, administered from 10 to 240 milligrams orally, once daily, showed no serious adverse events and no dose-dependent adverse events. Alzheimer’s is a disease of aging, the greatest risk-factor, but there is not a single therapy available to halt or reverse this chronic neurodegenerative disorder. Results in aged subjects demonstrated that on Day 16, with SAD/MAD daily oral dosing of placebo and NNI-362 at 120 mg and 240 mg, NNI-362 significantly reduced phosphoTau181 levels compared to baseline, while no reduction with placebo. PhosphoTau181 is a plasma measure of potential Alzheimer’s progression in brain. NNI-362 targets adult-born neuron regeneration and neuroprotection through a unique mechanism to promote translation and neuron survival (Sumien et al., 2021: in models of age-related disorders. This disease-agnostic neuron replacement / enhancement therapy aims to be a first-in-class oral therapy to halt and reverse Alzheimer’s and other age-related neurodegenerative disorders. The research reported in this press release was supported by NIA under award number R01AG056561. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About NNI-362 In aging patients, endogenous neuron regeneration is diminished. This diminution is exacerbated in patients suffering from neurodegeneration (for example, Alzheimer’s patients). NNI-362, Neuronascent’s lead, patented, new chemical entity, was developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegeneration. This ability supports the drug’s use to halt and reverse Alzheimer’s disease and other age-related neurodegenerative disorders. About Neuronascent, Inc. Neuronascent, Inc., [] a privately-held, clinical-stage pharmaceutical company, was founded to discover and develop novel therapies that treat CNS disorders with high-unmet need by replacing and enhancing neuron numbers, not just neural connections. Through its proprietary phenotypic screening platform, Neuronascent has discovered a pipeline of small molecule regenerative candidates with patents issued, including NNI-351 for Fragile X syndrome, a rare pediatric disorder. Safe Harbor Statement This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Corporate Contact:

Neuronascent Frequently Asked Questions (FAQ)

  • When was Neuronascent founded?

    Neuronascent was founded in 2004.

  • Where is Neuronascent's headquarters?

    Neuronascent's headquarters is located at 6030 Day Break Circle, Clarksville.

  • What is Neuronascent's latest funding round?

    Neuronascent's latest funding round is Unattributed - II.

  • How much did Neuronascent raise?

    Neuronascent raised a total of $1.36M.

  • Who are the investors of Neuronascent?

    Investors of Neuronascent include Maryland Department of Business & Economic Development and Jefferson Corner Group.

  • Who are Neuronascent's competitors?

    Competitors of Neuronascent include Viracta Therapeutics, Annovis Bio, CoMentis, Auspex Pharmaceuticals, ETEX Holdings and 12 more.

Compare Neuronascent to Competitors

OTO Medicine

OtoMedicine, Inc. aims to become a provider of medicines to prevent, treat and cure hearing loss. Based on over two decades of research at the University of Michigan, the company's lead product, AuraquellTM, is a combination of micronutrients that significantly aims to reduce noise induced hearing loss (NIHL) suffered by individuals continually exposed to loud noise in their work or recreational activities.

NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.


Mithridion is a biopharmaceutical company that discovers and develops drugs for neurodegenerative diseases, with a focus on Alzheimer's disease.


Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.